JP5933746B2 - イミダゾリジンジオン系化合物およびその用途 - Google Patents

イミダゾリジンジオン系化合物およびその用途 Download PDF

Info

Publication number
JP5933746B2
JP5933746B2 JP2014546301A JP2014546301A JP5933746B2 JP 5933746 B2 JP5933746 B2 JP 5933746B2 JP 2014546301 A JP2014546301 A JP 2014546301A JP 2014546301 A JP2014546301 A JP 2014546301A JP 5933746 B2 JP5933746 B2 JP 5933746B2
Authority
JP
Japan
Prior art keywords
compound
deuterated
group
mmol
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014546301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501820A5 (enExample
JP2015501820A (ja
Inventor
チェン，ユアンウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hc Pharmaceutical Co Ltd
Original Assignee
Hc Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hc Pharmaceutical Co Ltd filed Critical Hc Pharmaceutical Co Ltd
Publication of JP2015501820A publication Critical patent/JP2015501820A/ja
Publication of JP2015501820A5 publication Critical patent/JP2015501820A5/ja
Application granted granted Critical
Publication of JP5933746B2 publication Critical patent/JP5933746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014546301A 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途 Active JP5933746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110418859.0 2011-12-14
CN2011104188590A CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途
PCT/CN2012/086573 WO2013087004A1 (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途

Publications (3)

Publication Number Publication Date
JP2015501820A JP2015501820A (ja) 2015-01-19
JP2015501820A5 JP2015501820A5 (enExample) 2015-04-23
JP5933746B2 true JP5933746B2 (ja) 2016-06-15

Family

ID=48583248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546301A Active JP5933746B2 (ja) 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途

Country Status (9)

Country Link
US (1) US9346764B2 (enExample)
EP (1) EP2792674B1 (enExample)
JP (1) JP5933746B2 (enExample)
CN (2) CN103159680A (enExample)
AU (1) AU2012350482B2 (enExample)
CA (1) CA2859224C (enExample)
ES (1) ES2587903T3 (enExample)
PL (1) PL2792674T3 (enExample)
WO (1) WO2013087004A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6469092B2 (ja) * 2013-05-29 2019-02-13 ヒノバ ファーマシューティカルズ インコーポレイテッド イミダゾリジンジオン化合物及び薬物組成物
EP3046556A4 (en) * 2013-09-19 2017-04-26 Glaxosmithkline LLC Combination drug therapy
WO2015054804A1 (zh) * 2013-10-14 2015-04-23 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
US10131636B2 (en) * 2014-10-01 2018-11-20 Laurus Labs Limited Process for the preparation of Enzalutamide
CN106432090B (zh) * 2015-10-30 2019-08-20 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
CA3053805C (en) 2017-02-13 2020-06-30 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
AU2019241257B2 (en) * 2018-03-29 2025-02-20 Hinova Pharmaceuticals Inc. Deuterated imidazolidinedione compounds and their uses
US11753392B2 (en) 2018-04-13 2023-09-12 Hinova Pharmaceuticals Inc. Method for synthesis of deuterated amide and deuterated sulfonamide
CN110478347B (zh) * 2018-05-14 2021-07-02 海创药业股份有限公司 一种hc-1119制剂及其制备方法和用途
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
CN112442009B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 氘代化合物及其在治疗癌症方面的应用
CN115380026B (zh) * 2020-03-17 2023-11-07 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
JP2023537595A (ja) 2020-08-13 2023-09-04 ファイザー・インク 併用治療
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101431407B1 (ko) * 2005-05-13 2014-08-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
LT2656842T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
CA2648139A1 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
CN102482230B (zh) 2009-09-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives

Also Published As

Publication number Publication date
AU2012350482A1 (en) 2014-07-10
ES2587903T3 (es) 2016-10-27
AU2012350482B2 (en) 2017-02-16
EP2792674A1 (en) 2014-10-22
JP2015501820A (ja) 2015-01-19
CA2859224A1 (en) 2013-06-20
EP2792674B1 (en) 2016-05-25
CN104024228A (zh) 2014-09-03
PL2792674T3 (pl) 2016-12-30
WO2013087004A1 (zh) 2013-06-20
EP2792674A4 (en) 2015-06-17
CN103159680A (zh) 2013-06-19
US9346764B2 (en) 2016-05-24
US20140371284A1 (en) 2014-12-18
CN104024228B (zh) 2015-07-08
HK1198166A1 (en) 2015-03-13
CA2859224C (en) 2019-03-19

Similar Documents

Publication Publication Date Title
JP5933746B2 (ja) イミダゾリジンジオン系化合物およびその用途
JP6469092B2 (ja) イミダゾリジンジオン化合物及び薬物組成物
KR100674813B1 (ko) Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
JP7720099B2 (ja) 免疫調節剤としてのビアリール環結合芳香族複素環誘導体の調製およびその適用
CN115703761A (zh) 作为wwp1抑制剂的化合物及其应用
JP7665213B2 (ja) 三環系構造を有する芳香複素環式化合物、およびその調製方法と適用
KR101827660B1 (ko) 플루오로페닐 피라졸 화합물
CN113248474A (zh) 五元氮唑杂环衍生物及其制备方法和用途
CN119661432A (zh) 一种prmt5抑制剂及其药物组合物、药物制剂和用途
CN107739381B (zh) 莪术醇衍生物及其在制备抗肿瘤药物中的应用
JP7729632B2 (ja) 新規三環芳香族複素環化合物、ならびにその調製方法、医薬組成物および適用
CN114933601A (zh) 汉防己甲素衍生物及其制备方法和应用
JP2024518569A (ja) アルキルフェノール系化合物およびその製造方法
CN105085359A (zh) 含氮杂环取代的吡咯烷甲酰基硫代吗啉类dpp-iv抑制剂
KR102406248B1 (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
JP2579701B2 (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤
WO2024125662A1 (zh) 新型联芳环化合物作为免疫调节剂的制备和应用
CN117946165A (zh) 一种新型结构化合物axl抑制剂及其应用
CN117986249A (zh) 吡唑类衍生物抑制剂、其制备方法和应用
CN120309546A (zh) 一种苯并咪唑-2-硫代乙酰胺的衍生物化合物及其制备方法和应用
CN119143734A (zh) 作为at2r拮抗剂的杂环化合物及其用途
CN116888109A (zh) 作为Wee-1抑制剂的嘧啶化合物
HK1198166B (en) Imidazolidinedione compounds and their uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160502

R150 Certificate of patent or registration of utility model

Ref document number: 5933746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250